321 related articles for article (PubMed ID: 33054820)
1. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
Son KB
Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
[TBL] [Abstract][Full Text] [Related]
2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
3. The high price of "free" trade: U.S. trade agreements and access to medicines.
Lopert R; Gleeson D
J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
[TBL] [Abstract][Full Text] [Related]
4. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
5. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
[TBL] [Abstract][Full Text] [Related]
6. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
Son KB; Lee TJ
Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
[TBL] [Abstract][Full Text] [Related]
7. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
8. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
9. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
10. Confidentiality agreements: a challenge in market regulation.
Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
[TBL] [Abstract][Full Text] [Related]
11. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
12. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
Ooms G; Forman L; Williams OD; Hill PS
BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
[TBL] [Abstract][Full Text] [Related]
13. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
14. Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.
Wong ASY; Cole CB; Kohler JC
Global Health; 2021 Aug; 17(1):92. PubMed ID: 34416883
[TBL] [Abstract][Full Text] [Related]
15. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
16. Tackling reimbursement challenges to fair access to medicines - introduction to the topic.
Tachkov K; Savova A; Manova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):597-606. PubMed ID: 37055731
[TBL] [Abstract][Full Text] [Related]
17. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
Townsend B; Gleeson D; Lopert R
Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
[TBL] [Abstract][Full Text] [Related]
18. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
[TBL] [Abstract][Full Text] [Related]
19. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
Castro A; Westerhaus M
Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
[TBL] [Abstract][Full Text] [Related]
20. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
Faunce TA
Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
